Work

Relevance of Pathological Complete Response after Neoadjuvant Therapy for Breast Cancer

Year: 2016

Type: article

Abstract: Breast cancer is a heterogeneous disease, and the different biological subtypes have different prognostic impacts. Neoadjuvant trials have recently become popular as they offer several advantages compared to traditional adjuvant trials. Studies have shown that patients who achieve pathological complete response (pCR) after neoadjuvant treatment have a better long-term outcome. Consequently, increasing the rate of pCR became the end point of neoadjuvant trials with the expectation of translation into improved survival. However, the definition of pCR has lacked uniformity, and the prognostic impact of achievement of pCR on survival in different breast cancer subtypes is uncertain. In this review, we present the controversies associated with the use of pCR as an end point in neoadjuvant trials.

Source: Breast Cancer Basic and Clinical Research

DOI: 10.4137/bcbcr.s33163

Authors: Angela Pennisi, Thomas Kieber-Emmons, Issam Makhoul, Laura Hutchins

Institution: University of Arkansas for Medical Sciences

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,650